Healthcare Business

Medicine pills

Tabula Rasa Healthcare Updates Expected IPO Pricing

The U.S. Securities and Exchange Commission (SEC) has received an S-1 form from Tabula Rasa Healthcare regarding its initial public offering (IPO). The company intends to price its 4.3 million ...
Read Full Story »
IPO

Fulgent Genetics Announces Potential Pricing for IPO

Fulgent Genetics has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its IPO. The company expects to offer 4.6 million shares in an expected ...
Read Full Story »
biotech word cloud

Short Sellers Increase Bets in Major Biotechs

The short interest data are out for the most recent settlement date, September 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »
white pills

Major Pharma Continues to See Rising Tide in Short Interest

The short interest data have been released for the September 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
road fork sign

Pfizer Decides Against the Split

Pfizer Inc. (NYSE: PFE) shares traded down marginally Monday morning after the company announced that it will abandon its plan to split into two companies. This pharma giant has decided against this ...
Read Full Story »
FDA_logo

New Crohn’s Disease Drug Approved by FDA

Johnson & Johnson (NYSE: JNJ) is often not very vocal about receiving drug approvals, at least not using its own name. Janssen Biotech, a unit of Johnson & Johnson's Janssen ...
Read Full Story »
analysis

4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate

Monday is kicking off a very important week in the markets, with earnings season on the horizon and the first presidential debate later in the evening. Biotech and pharmaceutical companies ...
Read Full Story »
money

How Much Will Consumers Save on New Humira Biosimilar?

Some interesting news that hit late last week may have been much larger news had not been going into the weekend. In a time when government wrangling about drug prices ...
Read Full Story »
graph

6 Biotech and Biohealth Analyst Picks for 50% to 150% Upside

The world of biotech and pharmaceuticals has entered into a strange period. The presidential elections have many companies under fire over price control or price gouging issues. And valuations previously ...
Read Full Story »
thumbs up and down

Could Puma Biotech Double After This FDA Approval?

Puma Biotechnology Inc. (NYSE: PBYI) posted strong gains over the course of this past week, which began with some positive news from the U.S. Food and Drug Administration (FDA) and ...
Read Full Story »
Handshake

Endo Shuffles the Deck With New CEO Appointment

Shares of Endo International PLC (NASDAQ: ENDP) saw a handy gain in Friday’s session after the company announced a change in senior management. The company said that its board of directors ...
Read Full Story »
upside

Why Key Analyst Sees Puma Biotech Practically Doubling

Puma Biotechnology Inc. (NYSE: PBYI) has made solid gains over the course of this week, starting with some positive news from the U.S. Food and Drug Administration (FDA), but now ...
Read Full Story »
graph

Analyst Has 3 Biotech Stocks to Buy With Over 100% Upside Potential

Needless to say, the biotech world has had a very difficult year. Even the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, have suffered ...
Read Full Story »
FDA_logo

How Sarepta Is Cashing In on Its FDA Homerun

Sarepta Therapeutics Inc. (NASDAQ: SRPT) watched its stock practically double in just the past week alone following a key FDA approval. There were a few factors that played into this ...
Read Full Story »
Female patient on gurney

Eleven Bio Finds Even More Pipeline Growth in M&A

Eleven Biotherapeutics Inc. (NASDAQ: EBIO) has been gaining ever attention as 2016 has gone on. The stock traded as low as $0.25 a share this spring and as high as $6 this ...
Read Full Story »